Clinical Chemistry Link to Randox Laboratories Web Site spacer gif
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2006.082800v1, 2007; 10.1373/clinchem.2006.082800
This Article
Right arrow Full Text (PDF)
Right arrow 082800.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.082800v1
53/7/1280    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sieuwerts, A. M.
Right arrow Articles by Foekens, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sieuwerts, A. M.
Right arrow Articles by Foekens, J. A.

Received on November 7, 2006
Accepted on April 9, 2007

Cancer Diagnostics

Concentrations of TIMP1 mRNA Splice Variants and TIMP-1 Protein Are Differentially Associated with Prognosis in Primary Breast Cancer

Anieta M. Sieuwerts 1*, Pernille A. Usher 2, Marion E. Meijer-van Gelder 1, Mieke Timmermans 1, John W.M. Martens 1, Nils Brünner 2, Jan G.M. Klijn 1, Hanne Offenberg 2, John A. Foekens 1

1 Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
2 Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Copenhagen, Frederiksberg C, Denmark

* To whom correspondence should be addressed. E-mail: a.sieuwerts{at}erasmusmc.nl.

Background: TIMP-1 protein is a prognostic factor for recurrence-free and overall survival (OS) time in breast cancer. We evaluated the prognostic value of TIMP1 mRNA and a novel TIMP1 mRNA splice variant in 1301 primary breast cancer patients.

Methods: We measured mRNA transcripts of full-length TIMP1 (TIMP1-v1) and the novel splice variant lacking exon 2 (TIMP1-v2) by use of real-time RT-PCR in frozen primary tumor samples. Transcript concentrations are correlated with histomorphological and biological factors, TIMP-1 protein, and distant metastasis-free survival (MFS) and OS time.

TIMP1-v1 and TIMP1-v2 alone were not informative with respect to predicting prognosis. However, the PCR assay designed to measure the combination of v1 + v2 showed that high concentrations of this combination were associated with good prognosis. In Cox multivariate regression analysis, which also included the traditional prognostic factors, increasing concentrations were independently associated with prolonged MFS (P = 0.004) and OS (P = 0.048). Including TIMP-1 protein and TIMP1-v1+v2 mRNA together in the multivariate model revealed that protein and mRNA were both independently associated with prognosis, with hazard ratios pointing in opposite directions.

Conclusion: High concentrations of TIMP1-v1+2 mRNA are associated with good prognosis in patients with primary breast cancer. Since high concentrations of TIMP-1 protein are associated with poor prognosis, the presence of possible posttranscriptional mechanisms requires further investigation.




spacer gif
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Association for Clinical Chemistry.